Tariff Update: No Pause, Higher Rates on Japan Considered
Stock markets mistakenly assumed that the U.S. would end its tariff threats. Instead, President Trump said on Tuesday that he would not extend the July 9 deadline he imposed.Markets quickly reacted, as Nasdaq (QQQ) ended down by 0.82% on the day. The Dow Jones (DJI) rose, while the Russell 2000 (IWM) added 1.03%.Financial Times floated the idea of mini-trade deals closing before the July 9 deadline. Instead of bigger trade deals that would remove uncertainties, countries might agree on smaller deals. To raise the stakes, Trump expressed doubt that the U.S. would reach a deal with Japan. The President is now considering higher tariff rates in the 30% to 35% range. This is above the 24% proposed on Liberation Day.The Nikkei gained around 0.9% YTD. However, after the U.S. dollar lost 10%, the Japanese stock market is performing relatively well. Markets are cautious about their prospects. Toyota Motor (TM) lost around 12% in 2025, while Honda Motor (HMC) is up by 2.28%. Conversely, Sony Group (SONY) is up by 20% this year. Drug firm Takeda Pharmaceuticals (TAK) is up by 16%.Your TakeawayInvestors will watch for a trade agreement with the European Union next. The EU would likely accept a 10% universal tariff. Still, it would want exemptions for alcohol, pharmaceuticals, chip stocks, and commercial aircraft.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


